Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2009 1
2012 1
2013 1
2014 6
2015 20
2016 50
2017 70
2018 97
2019 110
2020 170
2021 207
2022 188
2023 166
2024 156

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.
Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ. Mullens W, et al. Eur J Heart Fail. 2019 Feb;21(2):137-155. doi: 10.1002/ejhf.1369. Epub 2019 Jan 1. Eur J Heart Fail. 2019. PMID: 30600580 Free article. Review.
The appropriate use of diuretics however remains challenging, especially when worsening renal function, diuretic resistance and electrolyte disturbances occur. This position paper focuses on the use of diuretics in heart failure with congestion. The manuscript addresses fr …
The appropriate use of diuretics however remains challenging, especially when worsening renal function, diuretic resistance and elect …
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Barrera-Chimal J, Girerd S, Jaisser F. Barrera-Chimal J, et al. Kidney Int. 2019 Aug;96(2):302-319. doi: 10.1016/j.kint.2019.02.030. Epub 2019 Mar 13. Kidney Int. 2019. PMID: 31133455 Free article. Review.
We also discuss the molecular mechanisms responsible for renoprotection related to MRAs that lead to reduced oxidative stress, inflammation, fibrosis, and hemodynamic alterations. The available clinical data support a benefit of MRA in reducing proteinuria in diabetic kidn …
We also discuss the molecular mechanisms responsible for renoprotection related to MRAs that lead to reduced oxidative stress, inflammation, …
Heart failure drug treatment.
Rossignol P, Hernandez AF, Solomon SD, Zannad F. Rossignol P, et al. Lancet. 2019 Mar 9;393(10175):1034-1044. doi: 10.1016/S0140-6736(18)31808-7. Lancet. 2019. PMID: 30860029 Review.
We offer views on the basis of our personal experience in research areas that have insufficient evidence. The best possible evidence-based drug treatment (including inhibitors of the renin-angiotensin-aldosterone system and beta blockers) is useful only when optimal …
We offer views on the basis of our personal experience in research areas that have insufficient evidence. The best possible evidence- …
Is Sacubitril/Valsartan Antifibrotic?
Zannad F, Ferreira JP. Zannad F, et al. J Am Coll Cardiol. 2019 Feb 26;73(7):807-809. doi: 10.1016/j.jacc.2018.11.041. J Am Coll Cardiol. 2019. PMID: 30784674 Free article. No abstract available.
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators. Anker SD, et al. Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16. Eur J Heart Fail. 2019. PMID: 31523904 Free article.
STUDY AIMS: The primary endpoint is the time-to-first-event analysis of the combined risk for cardiovascular death or hospitalization for heart failure. The trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all-cau …
STUDY AIMS: The primary endpoint is the time-to-first-event analysis of the combined risk for cardiovascular death or hospitalization …
Heart failure around the world.
Tromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, Lam CSP. Tromp J, et al. Eur J Heart Fail. 2019 Oct;21(10):1187-1196. doi: 10.1002/ejhf.1585. Epub 2019 Aug 16. Eur J Heart Fail. 2019. PMID: 31419004 Free article. Review.
Therefore, in this review, we evaluated (i) regional differences in patient characteristics and outcomes in recent epidemiologic studies; (ii) regional differences in worldwide representativeness of clinical trial populations; and (iii) the role of socioeconomic determinan …
Therefore, in this review, we evaluated (i) regional differences in patient characteristics and outcomes in recent epidemiologic studies; (i …
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Agarwal R, et al. Lancet. 2019 Oct 26;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X. Epub 2019 Sep 15. Lancet. 2019. PMID: 31533906 Clinical Trial.
Participants, the study team that administered treatments and measured blood pressure, and the investigators were masked to assigned treatment groups. Dose titrations were permitted after 1 week (patiromer) and 3 weeks (spironolactone). ...Persistent spironolactone enablem …
Participants, the study team that administered treatments and measured blood pressure, and the investigators were masked to assigned …
Is the Renin-Angiotensin-Aldosterone System Good for the Kidney in Acute Settings?
Dudoignon E, Dépret F, Legrand M. Dudoignon E, et al. Nephron. 2019;143(3):179-183. doi: 10.1159/000499940. Epub 2019 Apr 18. Nephron. 2019. PMID: 30999307 Free article. Review.
The renin-angiotensin-aldosterone system (RAAS) plays a major role in the regulation of blood pressure, renal hemodynamic, myocardial contractility via an enzymatic cascade leading to the synthesis of angiotensin 2. The activation of the RAAS system after acu …
The renin-angiotensin-aldosterone system (RAAS) plays a major role in the regulation of blood pressure, renal hemodynamic, myo …
Tailoring treatment of hyperkalemia.
Coutrot M, Dépret F, Legrand M. Coutrot M, et al. Nephrol Dial Transplant. 2019 Dec 1;34(Suppl 3):iii62-iii68. doi: 10.1093/ndt/gfz220. Nephrol Dial Transplant. 2019. PMID: 31800081
Finally, a growing body of evidence suggests that hyperkalemia might negatively impact outcomes in the long term in patients with chronic heart failure or kidney failure through underdosing or withholding of cardiovascular medication (e.g. renin-angiotensin-aldosterone …
Finally, a growing body of evidence suggests that hyperkalemia might negatively impact outcomes in the long term in patients with chronic he …
110 results